Related Articles
High farnesoid X receptor expression predicts favorable clinical outcomes in PD‑L1<sup>low/negative</sup> non‑small cell lung cancer patients receiving anti‑PD‑1‑based chemo‑immunotherapy
Efficacy analysis of immunotherapy‑based combinations for patients with EGFR‑mutant advanced non‑small cell lung cancer after TKI failure
The application of immunotherapy combined with taxanes in second‑line treatment of advanced HER2 negative gastric cancer
Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation
Irinotecan plus raltitrexed as second‑line chemotherapy for metastatic colorectal cancer: A retrospective study